TRAF3 and neoplasm: Inhibition of FGFRs is a promising therapeutic strategy, and phase I and II trials are progressing [39, 40] The tumor suppressor TRAF3 has previously been brought forward as a potential target for therapy development as it was inactivated in 20% of the HPV-positive tumors in the TCGA cohort.